ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2309건의 자료가 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 41 | Not yet recruiting | Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS | Acute Respiratory Distress Syndrome | Biological: Human umbilical cord mesenchymal stem cells + best supportive care Other: Placebo control + best supportive care |
Phase 2 | Baylx Inc. | INDUSTRY | 39 | All | 18 Years ~ 80 Years | |
| 40 | Withdrawn | Use of Hypochlorous Acid as Prophylaxis in Health Personnel at High Risk of Infection by SARS-CoV 2 (COVID19) | Infection Viral | Drug: Stabilized hypochlorous acid Drug: Placebo |
Phase 3 | Hospital Universitario San Ignacio, Pontificia Universidad Javeriana | OTHER | 0 | All | 18 Years ~ 80 Years | |
| 39 | Completed | Use of Inhaled High-molecular Weight Hyaluronan in Patients With Severe COVID19: Feasibility and Outcomes | Covid19 | Drug: HMW-HA | Phase 2 | Campus Bio-Medico University, National Institute of Environmental Health Sciences (NIEHS) | OTHER | 180 | All | 18 Years | Universita Campus Biomedico di Roma, Roma, Italy |
| 38 | Active, not recruiting | Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19 | Covid-19 | Biological: Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords | Early Phase 1 | Instituto de Medicina Regenerativa | INDUSTRY | 9 | All | 18 Years | Instituto de Medicina Regenerativa, Tijuana, Baja California, Mexico |
| 37 | Unknown status | Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting | Covid19 | Biological: BAMLANIVIMAB Biological: CASIRIVIMAB Biological: IMDEVIMAB |
Phase 2 | Sohail Rao | OTHER | 1000 | All | 12 Years | DHR Health Institute for Research and Development, Edinburg, Texas, United States DHR Health, Edinburg, Texas, United States Starr County Memorial Hospital, Rio Grande City, Texas, United States |
| 36 | Completed | Use of Multiple Doses of Convalescent Plasma in Mechanically Intubated Patients With COVID-19 | COVID-19 | Biological: Multiple doses of anti-SARS-CoV-2 Convalescent Plasma | Early Phase 1 | Hospital Regional Dr. Rafael Estevez, Complejo Hospitalario Dr. Arnulfo Arias Madrid, Hospital Santo Tomas, Hospital Punta Pacifica, Pacifica Salud, Insituto Conmemorativo Gorgas de Estudios para la Salud, Sociedad Panamena de Hematologia, Institute of Scientific Research and High Technology Services (INDICASAT AIP), University of Panama, Sistema Nacional de Investigacion de Panama | OTHER | 30 | All | 18 Years | 1. Complejo Hospitalario Metropolitano Arnulfo Arias Madrid, Caja de Seguro Social, Panama, Panama |
| 35 | Completed | Use of UC-MSCs for COVID-19 Patients | COVID-19 | Biological: Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care. Other: Vehicle + Heparin along with best supportive care |
Phase 2 | Camillo Ricordi | OTHER | 24 | All | 18 Years | Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida, United States |
